Zydus receives final approval from the USFDA for Valsartan and Hydrochlorothiazide Tablets

Deepthi | Myequity news | Date : 16-03-2019 12:28:00 IST

Zydus Cadila has received the final approval from the USFDA to market Valsartan and Hydrochlorothiazide Tablets USP (USRLD Diovan HCT Tablets) in the strengths of 80mg / 12.5mg, 160 mg/ 12.5 mg, 160mg /25mg, 320mg/12.5mg, and 320mg/ 25mg. The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

More from Myequity